Polizzi is part of the Morrison & Foerster team conducting patent work on behalf of Juno Therapeutics Inc., a biotechnology company that is developing innovative methods for fighting cancer. The Seattle-based company raised more than $264 million through its high-profile initial public offering at the end of last year.
"IP forms a very central role in an IPO. Having to get all of your ducks in a row is very important," Polizzi said. "You have ...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In